Abdulrahman Alshaya, BCCCP, BCPS, PharmD
National Guard Health Affairs - Central Region
Riyadh, Saudi Arabia
Disclosure information not submitted.
Mohammed Aldhaeefi, PharmD
Assistant Professor of Pharmacy Practice
King Saud bin Abdulaziz University for Health Sciences
Boston, Massachusetts, Saudi Arabia
Disclosure information not submitted.
Qusai Alhamdan, PharmD student
PharmD student
King Saud bin Abdulaziz University for Health Sciences, United States
Disclosure information not submitted.
Farris Alamody, PharmD student
PharmD student
King Saud bin Abdulaziz University for Health Sciences, United States
Disclosure information not submitted.
Mohammed Almosalem, PharmD student
PharmD student
King Saud bin Abdulaziz University for Health Sciences, United States
Disclosure information not submitted.
Khalid Al Sulaiman, MBA, BCCCP, , BCNSP
Consultant, Critical Care Clinical Pharmacist
King Abdulaziz Medical City, Riyadh, Saudi Arabia
Riyadh, Saudi Arabia
Disclosure information not submitted.
Shuroug Alowais, BSc, Pharm, PharmD, BCPS
Assistant Professor of Pharmacy Practice
King Saud bin Abdulaziz University for Health Sciences, United States
Disclosure information not submitted.
Khalid Bin Saleh, BSc, Pharm, PharmD, BCPS
Assistant Professor of Pharmacy Practice
King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia
Disclosure information not submitted.
Title: Predictors for acute kidney injury for septic patients treated with colistin
Introduction: Intravenous (IV) colistin is commonly used for multidrug-resistant gram-negative infections. It is primarily eliminated renally and may induce acute kidney injury (AKI) in up to 53% of those who received colistin. Septic patients may need to be started on colistin and have an additional risk of developing AKI. We aimed to assess predictors for colistin-induced AKI amongst septic patients.
Methods: This is a retrospective cohort study at a tertiary teaching hospital in Saudi Arabia. Adult septic patients with Gram-negative infections admitted to the hospital from May 2016 to January 2020 were screened after obtaining IRB approval. AKI was defined based on the AKIN criteria. We investigated AKI risk factors such as the development of septic shock, the severity of illness, and medication co-administration using a multiple logistic regression model.
Results: One hounded and three patients were included in the analysis. Of the included predictors, development of septic shock (OR: 3.75; 95% CI 1.18 – 13.15), carbapenem co-administration (OR: 3.96; 95% CI 1.134 – 15.57) were associated with increased risk of AKI. Other factors include the history of chronic kidney disease, administration of colistin loading dose, co-administration of aminoglycosides, piperacillin-tazobactam or sulfamethoxazole, and trimethoprim were not significant predictors.
Conclusion: co-administration of carbapenems and the development of septic shock may carry additional risk in inducing AKI amongst adult septic patients treated with IV colistin.